Peer-influenced content. Sources you trust. No registration required. This is HCN.
Medical Professionals Reference (MPR)
Approved for AD in adults a year ago, abrocitinib is now available for individuals over 12 years old with moderate to severe atopic dermatitis that is not adequately controlled with other systemic therapy.
Dermatology February 23rd 2023
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS